HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Woodruff, T. M. Articles by Taylor, S. M. Search for Related Content PubMed PubMed Citation Articles by Woodruff, T. M. Articles by Taylor, S. M.

A Potent Human C5a Receptor Antagonist Protects against Disease Pathology in a Rat Model of Inflammatory Bowel Disease ¹

Trent M. Woodruff^*, Thiruma V. Arumugam^*, Ian A. Shiels^*,, Robert C. Reid, David P. Fairlie and Stephen M. Taylor^2,*,

^* Department of Physiology and Pharmacology, School of Biomedical Sciences and Institute for Molecular Bioscience, University of Queensland, and Promics, Brisbane, Australia

The complement system is implicated in the pathogenesis of human inflammatory bowel disease, but the specific role of C5a has never been examined. We have compared the efficacy of an orally active human C5a receptor antagonist (AcPhe[Orn-Pro-D-cyclohexylalanine-Trp-Arg]), prednisolone, and infliximab against trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats. The drugs were administered either 2 days before or 24 h after TNBS instillation, and rats were then examined after 8 days. Drug-free colitis control rats showed severe disease pathology with significant mortality (39%). Rats pre or posttreated with the C5a antagonist (10 mg/kg/day peroral, 0.3 mg/kg/day s.c.) had reduced mortality and significantly improved macroscopic scores, colon edema, colon myeloperoxidase levels, reduced concentrations of TNF- levels in the colon and serum, and had greater food intake resulting in greater weight gains than colitis-only rats. Rats pretreated with prednisolone (1 mg/kg/day s.c.) displayed significant improvement in parameters measured, but posttreatment was ineffective. Single dose pretreatment with the TNF- inhibitor infliximab (3 mg/kg i.v.) also had significant improvements in the parameters measured. Rats pretreated with a combination of the C5a antagonist and prednisolone showed no greater improvements than either drug alone. These findings suggest a central role for complement, particularly C5a, in the pathology of TNBS-induced colitis in rats, indicating a possible therapeutic role for C5a antagonists in inflammatory bowel disease.

This article has been cited by other articles:

				S. O. Carrigan, D. B. S. Pink, and A. W. Stadnyk Neutrophil transepithelial migration in response to the chemoattractant fMLP but not C5a is phospholipase D-dependent and related to the use of CD11b/CD18 J. Leukoc. Biol., December 1, 2007; 82(6): 1575 - 1584. [Abstract] [Full Text] [PDF]

				C. E. Vergunst, D. M. Gerlag, H. Dinant, L. Schulz, M. Vinkenoog, T. J. M. Smeets, M. E. Sanders, K. A. Reedquist, and P. P. Tak Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation Rheumatology, December 1, 2007; 46(12): 1773 - 1778. [Abstract] [Full Text] [PDF]

				P. Buanne, E. Di Carlo, L. Caputi, L. Brandolini, M. Mosca, F. Cattani, L. Pellegrini, L. Biordi, G. Coletti, C. Sorrentino, et al. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice J. Leukoc. Biol., November 1, 2007; 82(5): 1239 - 1246. [Abstract] [Full Text] [PDF]

				R. Barbuio, M. Milanski, M. B Bertolo, M. J Saad, and L. A Velloso Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet J. Endocrinol., September 1, 2007; 194(3): 539 - 550. [Abstract] [Full Text] [PDF]

				T. M. Woodruff, J. W. Crane, L. M. Proctor, K. M. Buller, A. B. Shek, K. de Vos, S. Pollitt, H. M. Williams, I. A. Shiels, P. N. Monk, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration FASEB J, July 1, 2006; 20(9): 1407 - 1417. [Abstract] [Full Text] [PDF]

				H. Patel, R. A.G. Smith, S. H. Sacks, and W. Zhou Therapeutic Strategy with a Membrane-Localizing Complement Regulator to Increase the Number of Usable Donor Organs after Prolonged Cold Storage J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1102 - 1111. [Abstract] [Full Text] [PDF]

				T. M. Woodruff, S. Pollitt, L. M. Proctor, S. Z. Stocks, H. D. Manthey, H. M. Williams, I. B. Mahadevan, I. A. Shiels, and S. M. Taylor Increased Potency of a Novel Complement Factor 5a Receptor Antagonist in a Rat Model of Inflammatory Bowel Disease J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 811 - 817. [Abstract] [Full Text] [PDF]

				A. H. J. Kim, I. D. Dimitriou, M. C. H. Holland, D. Mastellos, Y. M. Mueller, J. D. Altman, J. D. Lambris, and P. D. Katsikis Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses J. Immunol., August 15, 2004; 173(4): 2524 - 2529. [Abstract] [Full Text] [PDF]

				D. R. March, L. M. Proctor, M. J. Stoermer, R. Sbaglia, G. Abbenante, R. C. Reid, T. M. Woodruff, K. Wadi, N. Paczkowski, J. D. A. Tyndall, et al. Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and Activity Mol. Pharmacol., April 1, 2004; 65(4): 868 - 879. [Abstract] [Full Text]

				F. Lin, D. Spencer, D. A. Hatala, A. D. Levine, and M. E. Medof Decay-Accelerating Factor Deficiency Increases Susceptibility to Dextran Sulfate Sodium-Induced Colitis: Role for Complement in Inflammatory Bowel Disease J. Immunol., March 15, 2004; 172(6): 3836 - 3841. [Abstract] [Full Text] [PDF]